Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates

Drug Discovery Today

Volumn 18, Issue 1-2, 2013, Pages 58-70

  Southan, Christopher ^a   Williams, Antony J ^b   Ekins, Sean ^c  

^a ChrisDS Consulting   (Sweden)

^b ROYAL SOCIETY OF CHEMISTRY   (United Kingdom)

^c Collaborations in Chemistry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CE 210666; CEDIRANIB; DOXAPRAM; GEFITINIB; GSK 1004723 D; NEFAZODONE; SARACATINIB; SULFADOXINE; UNCLASSIFIED DRUG; ZIBOTENTAN;

COMPUTER MODEL; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DATABASE; DRUG DESIGN; DRUG FORMULATION; DRUG INDICATION; DRUG LABELING; DRUG QUALITY; DRUG REPOSITIONING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG UTILIZATION; PATENT; PHARMACODYNAMICS; REVIEW;

COMPUTER SIMULATION; DRUG DESIGN; DRUG INDUSTRY; DRUG REPOSITIONING; GREAT BRITAIN; HUMANS; TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 84871927881     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2012.11.005     Document Type: Review

References (113)

1. The PubChem Database, available at: http://pubchem.ncbi.nlm.nih.gov/
2. Y. Wang PubChem: a public information system for analyzing bioactivities of small molecules Nucleic Acids Res. 37 Web Server issue 2009 W623 W633
3. ChemSpider, available at: http://www.chemspider.com/
4. A.J. Williams Internet-based tools for communication and collaboration in chemistry Drug Discov. Today 13 2008 502 506
5. H.E. Pence, and A.J. Williams ChemSpider: an online chemical information resource J. Chem. Educ. 87 2010 1123 1124
6. A.J. Williams Public chemical compound databases Curr. Opin. Drug Discov. Dev. 11 2008 393 404
7. ChEMBL, available at: https://www.ebi.ac.uk/chembldb/index.php
8. eMolecules, available at: http://www.emolecules.com/
9. D.S. Wishart DrugBank: a knowledgebase for drugs, drug actions and drug targets Nucleic Acids Res. 36 Database issue 2008 D901 D906
10. A.J. Williams Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation Drug Discov. Today 17 2012 685 701
11. G. Nicola Public domain databases for medicinal chemistry J. Med. Chem. 55 2012 6987 7002
12. S. Ekins Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis Mol. Biosyst. 6 2010 2316 2324
13. IBM Patents and NIH, available at: http://www-935.ibm.com/services/us/ gbs/bao/siip/nih/
14. A. Heifets, and I. Jurisica SCRIPDB: a portal for easy access to syntheses, chemicals and reactions in patents Nucleic Acids Res. 40 Database issue 2012 D428 D433
15. Thomson Reuters, available at: http://thomsonreuters.com/
16. T.I. Oprea, and J. Mestres Drug repurposing: far beyond new targets for old drugs AAPS J. 14 2012 759 763
17. S.J. Weir Repurposing approved and abandoned drugs for the treatment and prevention of cancer through public-private partnership Cancer Res. 72 2012 1055 1058
18. Drug Repositioning Wikipedia Article, available at: http://en.wikipedia. org/wiki/Drug-repositioning
19. A.J. Williams, and S. Ekins A quality alert and call for improved curation of public chemistry databases Drug Discov. Today 16 2011 747 750
20. S. Ekins In silico repositioning of approved drugs for rare and neglected diseases Drug Discov. Today 16 2011 298 310
21. S. Ekins, and A.J. Williams Finding promiscuous old drugs for new uses Pharm. Res. 28 2011 1786 1791
22. Y.Y. Li A computational approach to finding novel targets for existing drugs PLoS Comput. Biol. 7 2011 e1002139
23. C.L. Beaulieu Towards the development of a generalizable pre-clinical research pathway for orphan disease therapy Orphanet J. Rare Dis. 7 2012 39
24. J.T. Dudley Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease Sci. Transl. Med. 3 2011 96ra76
25. J.T. Dudley Exploiting drug-disease relationships for computational drug repositioning Brief Bioinform. 12 2011 303 311
26. T. Cohen Discovering discovery patterns with predication-based Semantic Indexing J. Biomed. Inform. 2012 10.1016/j.jbi.2012.07.003 [Epub ahead of print]
27. D.J. Wild Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research Drug Discov. Today 17 2012 469 474
28. E. Pihan e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design Bioinformatics 28 2012 1540 1541
29. A. Mullard Drug repurposing programmes get lift off Nat. Rev. Drug Discov. 11 2012 505 506
30. M. Allison NCATS launches drug repurposing program Nat. Biotechnol. 30 2012 571 572
31. NCATS, available at: http://www.ncats.nih.gov/research/reengineering/ rescue-repurpose/therapeutic-uses/directory.html
32. S.L. Kinnings Drug discovery using chemical systems biology: repositioning the safe medicine Comtan to treat multi-drug and extensively drug resistant tuberculosis PLoS Comput. Biol. 5 2009 e1000423
33. Y. Cho Drug repositioning and pharmacophore identification in the discovery of hookworm MIF inhibitors Chem. Biol. 18 2011 1089 1101
34. F. Iorio Discovery of drug mode of action and drug repositioning from transcriptional responses Proc. Natl. Acad. Sci. U. S. A. 107 2010 14621 14626
35. S.J. Cockell An integrated dataset for in silico drug discovery J. Integr. Bioinform. 7 2010 116
36. X.A. Qu Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships BMC Bioinform. 10 Suppl. 5 2009 4
37. Collabchem blog 2, available at: http://www.collabchem.com/2012/08/21/ collaborations-to-get-the-ncats-library-of-industry-provided-reagents/
38. Collabchem blog 1, available at: http://www.collabchem.com/2012/07/18/ petition-ncats-to-release-structures-for-library-of-industry-provided-reagents/
39. blog 1, available at: http://cdsouthan.blogspot.se/2012/07/ncats- repurposing-candiates-matching.html
40. blog 2, available at: http://cdsouthan.blogspot.se/2012/08/ncats.html
41. ACS Drug Repurposing Abstracts 2012, available at: http://abstracts.acs. org/chem/244nm/program/divisionindex.php?nl=1&act=presentations&val= Cheminformatics+and+Drug+Repurposing&ses= Cheminformatics+and+Drug+Repurposing&prog=114459
42. A.B. Wagner SciFinder Scholar 2006: an empirical analysis of research topic query processing J. Chem. Inf. Model. 46 2006 767 774
43. Thomson Reuters Integrity, available at: http://thomsonreuters.com/ products-services/science/science-products/a-z/integrity/
44. MRC, available at: http://www.mrc.ac.uk/Fundingopportunities/Calls/MoD/ MRC008389
45. PubChem Search, available at: http://www.ncbi.nlm.nih.gov/sites/entrez/? db=pccompound&term=JNJ-39393406
46. Federal Food, Drug, and Cosmetic Act (FD&C Act), available at: http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/default.htm
47. Pharmaceutical Drug, available at: http://en.wikipedia.org/wiki/ Pharmaceutical-drug
48. Can Chicken Feathers and American Cockroaches be Pharmaceutically Active? Available at: http://www.chemconnector.com/2011/07/28/can-chicken-feathers-and- american-cockroaches-be-pharmaceutically-active/
49. Investigational New Drug (IND) Application, available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ InvestigationalNewDrugINDApplication/default.htm#Introduction
50. FDA Databases, available at: http://www.fda.gov/Drugs/InformationOnDrugs/ default.htm
51. Dedicating Christmas Time to the Cause of Curating Wikipedia, available at: http://www.chemconnector.com/2008/01/09/dedicating-christmas-time-to-the- cause-of-curating-wikipedia/
52. Rousvastatin, available at: http://en.wikipedia.org/wiki/Rosuvastatin
53. R. Huang The NCGC Pharmaceutical Collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics Sci. Transl. Med. 3 2011 80ps16
54. PubChem BioAssay ID 1195, available at: http://www.ncbi.nlm.nih.gov/ pccompound?linkname=pcassay-pccompound-active&from-uid=1195
55. C.D. Southan Quantitative assessment of the expanding complementarity between public and commercial databases of bioactive compounds J. Cheminform. 1 2009 10
56. Therapeutic Target Database, available at: http://bidd.nus.edu.sg/group/ cjttd/
57. F.F. Hefti Requirements for a lead compound to become a clinical candidate BMC Neurosci. 9 Suppl. 3 2008 7
58. Pharmaprojects, available at: http://library.dialog.com/bluesheets/html/ bl0128.html
59. Thomson Reuters Pharma, available at: http://thomsonreuters.com/products- services/science/science-products/a-z/thomson-pharma/#tab2
60. CandiStore, available at: http://chembl.blogspot.co.uk/2009/02/ candistore.html
61. IUPAC, available at: http://www.chem.qmul.ac.uk/iupac/
62. USANs, available at: http://www.ama-assn.org/ama/pub/physician-resources/ medical-science/united-states-adopted-names-council/adopted-names.page ?
63. WHO, available at: http://www.who.int/en/
64. USAN, available at: http://www.ama-assn.org/ama/pub/physician-resources/ medical-science/united-states-adopted-names-council.page
65. 348U87 in PubChem, available at: http://pubchem.ncbi.nlm.nih.gov/summary/ summary.cgi?cid=9554761&loc=ec-rcs
66. MeSH, available at: http://www.ncbi.nlm.nih.gov/mesh
67. PubMed, available at: http://www.ncbi.nlm.nih.gov/pubmed
68. Drugs.com, available at: http://www.drugs.com/drug-information.html
69. Drugs.com International, available at: http://www.drugs.com/ international/
70. M. Kanehisa, and S. Goto KEGG: kyoto encyclopedia of genes and genomes Nucleic Acids Res. 28 2000 27 30
71. Therapeutic Targets Database, available at: http://bidd.nus.edu.sg/group/ cjttd/
72. T. Bartfai, and G.V. Lees Drug Discovery: From Bedside to Wall Street 2005 Academic Press
73. C. Tyrchan Exploiting structural information in patent specifications for key compound prediction J. Chem. Inf. Model. 52 2012 1480 1489
74. H. Zhao, and Z. Guo Medicinal chemistry strategies in follow-on drug discovery Drug Discov. Today 14 2009 516 522
75. M.J. Waring Property based optimisation of glucokinase activators-discovery of the phase IIb clinical candidate AZD1656 Med. Chem. Commun. 3 2012 1077 1081
76. D.P. Becker Orally active MMP-1 sparing alpha-tetrahydropyranyl and alpha-piperidinyl sulfone matrix metalloproteinase (MMP) inhibitors with efficacy in cancer, arthritis, and cardiovascular disease J. Med. Chem. 53 2010 6653 6680
77. R.R. Bell Skin wound healing in the SKH-1 female mouse following inducible nitric oxide synthase inhibition Br. J. Dermatol. 157 2007 656 661
78. T.A. Esbenshade Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist J. Pharmacol. Exp. Ther. 343 2012 233 245
79. J. Fukushige Exercise-induced ventricular arrhythmia after repair of tetralogy of Fallot Acta Paediatr. Jpn. 31 1989 30 34
80. I.V. Filippov, and M.C. Nicklaus Optical structure recognition software to recover chemical information: OSRA, an open source solution J. Chem. Inf. Model. 49 2009 740 743
81. M. Swain chemicalize.org J. Chem. Inf. Model. 52 2012 613 615
82. Chemicalize, available at: http://www.chemicalize.org/
83. D.M. Lowe Chemical name to structure: OPSIN, an open source solution J. Chem. Inf. Model. 51 2011 739 753
84. OPSIN, available at: http://opsin.ch.cam.ac.uk/
85. T.T. Wager Discovery of two clinical histamine H(3) receptor antagonists: trans-N-ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidinylmethyl)phenyl] cyclobutanecarbox amide (PF-03654746) and trans-3-fluoro-3-[3-fluoro-4- (pyrrolidin-1-ylmethyl)phenyl]-N-(2-methylpropyl)cyc lobutanecarboxamide (PF-03654764) J. Med. Chem. 54 2011 7602 7620
86. Anon., PF-03654747 Wikipedia page, available at: http://en.wikipedia.org/ wiki/PF-03654746
87. NCATS Webpage, available at: http://www.ncats.nih.gov/research/ reengineering/rescue-repurpose/therapeutic-uses/directory.html
88. NCATS Compounds with Identification, available at: http://figshare.com/ articles/NCats-Compounds-with-identifications/92850
89. NCATS and MRC CIDs, available at: http://www.ncbi.nlm.nih.gov/sites/ myncbi/collections/public/12yco7P7tlW-ZXra2GPnVLM54/
90. S. Ekins, and A.J. Williams When pharmaceutical companies publish large datasets: an abundance of riches or Fool's Gold? Drug Discov. Today 15 2010 812 815
91. S. Ekins, and A.J. Williams Meta-analysis of molecular property patterns and filtering of public datasets of antimalarial "hits" and drugs MedChemComm 1 2010 325 330
92. Smartsfilter, available at: http://pasilla.health.unm.edu/tomcat/biocomp/ smartsfilter
93. M. Hann Strategic pooling of compounds for high-throughput screening J. Chem. Inf. Comput. Sci. 39 1999 897 902
94. J.F. Blake Identification and evaluation of molecular properties related to preclinical optimization and clinical fate Med. Chem. 1 2005 649 655
95. J.F. Blake Examination of the computed molecular properties of compounds selected for clinical development Biotechniques Suppl. 2003 16 20
96. J.B. Baell, and G.A. Holloway New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 53 2010 2719 2740
97. J.R. Huth Toxicological evaluation of thiol-reactive compounds identified using a la assay to detect reactive molecules by nuclear magnetic resonance Chem. Res. Toxicol. 20 2007 1752 1759
98. J.R. Huth ALARM NMR: a rapid and robust experimental method to detect reactive false positives in biochemical screens J. Am. Chem. Soc. 127 2005 217 224
99. S. Ekins, and J.S. Freundlich Validating new tuberculosis computational models with public whole cell screening aerobic activity datasets Pharm. Res. 28 2011 1859 1869
100. S. Ekins Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery Trends Microbiol. 19 2011 65 74
101. S. Ekins A collaborative database and computational models for tuberculosis drug discovery Mol. Biosyst. 6 2010 840 851
102. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
103. D.F. Veber Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623
104. S. Ekins A predictive ligand-based Bayesian model for human drug induced liver injury Drug Metab. Dispos. 38 2010 2302 2308
105. Y.C. Martin Do structurally similar molecules have similar biological activity? J. Med. Chem. 45 2002 4350 4358
106. Approved Drugs Mobile App, available at: https://itunes.apple.com/us/app/ approved-drugs/id534198253
107. A.J. Williams Why open drug discovery needs four simple rules for licensing data and models PLoS Comput. Biol. 2012 10.1371/journal.pcbi.1002706 [Epub ahead of print]
108. S. Orchard Minimum information about a bioactive entity (MIABE) Nat. Rev. Drug Discov. 10 2011 661 669
109. SMILES on Wikipedia, available at: http://en.wikipedia.org/wiki/SMILES
110. InChI on Wikipedia, available at: http://en.wikipedia.org/wiki/ International-Chemical-Identifier
111. genenames, available at: http://www.genenames.org/
112. Pistoia Alliance, available at: http://pistoiaalliance.org/
113. Open PHACTS, available at: http://www.openphacts.org/